Table 1.
Mutation status and IC50(μM) for Dovitinib and Oxaliplatin in Colon cancer cell lines
|
Cell Lines |
HCT-116 | HT-29 | SW-480 | CaCO2 | LS174T |
|---|---|---|---|---|---|
|
Status
| |||||
| Drugs | |||||
|
KRAS |
M(Gly13Asp) |
WT |
M(Gly12Val) |
WT |
M(Gly12Asp) |
|
BRAF |
WT |
M(Val600Glu) |
WT |
M(Val600Glu) |
WT |
|
PIK3CA/pTEN |
M |
WT |
WT |
WT |
M |
|
p53 |
WT |
M (273Arg-His) |
M (273Arg-His |
M |
WT |
|
309Pro-ser) | |||||
|
LOH/MSI |
MSI |
MSS/LOH |
MSS/LOH |
MSS |
MSI |
|
APC |
WT |
M |
M |
M |
WT |
|
Dovitinib |
3.050.58 |
5.21.93 |
4.330.47 |
3.230.64 |
4.330.47 |
| Oxaliplatin | 1.670.17 | 8.02.0 | 6.02.08 | 2.70.15 | 2.871.27 |
Abbreviations: M Mutant, WT Wild type, LOH Loss of heterozygosity, MSI Microsatellite instability, MSS Microsatellite stable.